Association of Systemic Lupus Erythematosus with Dyslipidemia

Muhammad Imran; Hajra Ahmad; Alam Zeb; Najib Ullah; Usman Ali; Almas Khan

doi:10.51253/pafmj.v76i1.11665

Authors

Muhammad Imran Department of Rheumatology, Khyber Teaching Hospital, Peshawar Pakistan
Hajra Ahmad Department of Rheumatology, Khyber Teaching Hospital, Peshawar Pakistan
Alam Zeb Department of Rheumatology, Khyber Teaching Hospital, Peshawar Pakistan
Najib Ullah Department of Rheumatology, Khyber Teaching Hospital, Peshawar Pakistan
Usman Ali Department of Rheumatology, Khyber Teaching Hospital, Peshawar Pakistan
Almas Khan Department of Medicine, Khyber Teaching Hospital, Peshawar Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i1.11665

Keywords:

Cholesterol, High Density Lipoprotein, Lipid Profile, Systemic Lupus Erythematosus

Abstract

Objective: To find out the association between Systemic Lupus Erythematosus (SLE) disease activity and lipid profile of patients.

Study Design: Cross Sectional Study.

Place and Duration of Study: Khyber Teaching Hospital, Peshawar Pakistan, from May 2023 to Feb 2024.

Methodology: Seventy-eight patients of Systemic Lupus Erythematosus (SLE), were recruited using non-probability consecutive. Apart from patient demographics, SLE disease activity was calculated, and lipid profiles were sent to hospital laboratory sent to hospital laboratory. Correlation between SLE disease activity and different parameters was checked.

Results: Our study of 78 patients revealed a predominantly female population 63(80.7%) with moderate disease activity 54(69.2%). Notably, abnormal lipid profiles were observed, with significant positive correlations found between SLE Disease Activity Index (SLEDAI) and Total Cholesterol (r=0.702, p=<0.001), Triglycerides (r=0.238, p=0.038), and Low-Density Lipoprotein (LDL) (r=0.633, p=<0.001). High-Density Lipoprotein (HDL) exhibited a non-significant correlation (r=0.074, p=0.519), while duration of disease showed minimal impact (r=-0.045, p=0.699).

Conclusion: The study demonstrated a significant correlation between SLE Disease Activity Index (SLEDAI) and total cholesterol, low density lipoproteins and triglycerides.

Downloads

Download data is not yet available.

References

1. Huang S, Zhang Z, Cui Y, Yao G, Ma X, Zhang H. Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosus. Clin Rheumatol 2023; 1: 1-8.

https://doi.org/10.1007/s10067-023-06539-2

2. Rezaeian M, Abbasi A, Abbasifard M. Association between Abnormal Lipid Levels and Systemic Lupus Erythematosus. Rheumatol Res 2021; 6(2): 81–86.

https://doi.org/10.22631/rr.2021.69997.1118

3. Sajjad S, Farman S, Ahmed M, Mir N, Azeem B. Frequency of Dyslipidemia in patients with Lupus Nephritis. Pak J Med Sci 2017: 33(2): 358. https://doi.org/10.12669/pjms.332.12410

4. Zhou B, Xia Y, She J. Dysregulated serum lipid profile and its correlation to disease activity in young female adults diagnosed with systemic lupus erythematosus: a cross-sectional study. Lipids Health Dis 2020; 19(1): 40.

https://doi.org/10.1186/s12944-020-01232-8

5. Kumarasamy R, Rajendran B. Study on Lupus Pattern of Dyslipidemia in Systemic Erythematosus. Sch Int J Biochem 2019; 2(2): 31-35. https://doi.org/10.36348/sijb.2019.v02i02.004

6. Ding Y, Fan S, Tang Y, He M, Ren M, Shi Y, et al. The Association between Blood Lipids and Systemic Lupus Erythematosus: A Two-Sample Mendelian Randomization. Res Metab 2023; 13(1): 27. https://doi.org/10.3390/metabo13010027

7. Nisar A, Rasheed U, Aziz W, Farooqi AZ. Prevalence of dyslipidemias in autoimmune rheumatic diseases. J Coll Physicians Surg Pak 2012; 22(4): 235–239.

8. Ali M, Mostafa S, Sayed A. Clinical significance of lipid profile in systemic lupus erythematosus patients: Relation to disease activity and therapeutic potential of drugs. Egypt Rheumatol 2017; 39(2): 93–98. https://doi.org/10.1016/j.ejr.2016.08.004

9. Chen W, Wang Q, Zhou B, Zhang L, Zhu H. Lipid Metabolism Profiles in Rheumatic Diseases. Front Pharmacol 2021; 12: 643520. https://doi.org/10.3389/fphar.2021.643520

10. Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just comorbidity? Semin Arthritis Rheum 2016; 45(5): 604–610.

https://doi.org/10.1016/j.semarthrit.2015.10.010

11. Khalil F, Rafat MN, Beltagy NTE, Gaber HA. Study of Dyslipidemia in Patients with Systemic Lupus Erythematosus and its Correlation to Disease Activity. Egypt J Hosp Med 2018; 73(5): 6586–6595. https://doi.org/10.21608/EJHM.2018.15588

12. Arora S, Isenberg DA, Castrejon I. Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. Arthritis Care Res 2020; 72(S10): 27–46.

https://doi.org/10.1002/acr.24221

13. Yuan J, Li LI, Wang Z, Song W, Zhang Z. Dyslipidemia in patients with systemic lupus erythematosus: Association with disease activity and B-type natriuretic peptide levels. Biomed Rep 2016; 4(1): 68-72. https://doi.org/10.3892/br.2015.544

14. Szabó MZ, Szodoray P, Kiss E. (2017). Dyslipidemia in systemic lupus erythematosus. Immunologic Research 2017; 65(2): 543–550. https://doi.org/10.1007/s12026-016-8892-9

15. Wang M, Huang S, Lin X, Wen C, He Z, Huang L. The causal relationship between blood lipids and systemic lupus erythematosus risk: a bidirectional two-sample mendelian randomization study. Front Genet 2022; 13: 858653.

https://doi.org/10.3389/fgene.2022.858653

16. Atta AM, Silva JP, Santiago MB, Oliveira IS, Oliveira RC, Sousa Atta ML. Clinical and laboratory aspects of dyslipidaemia in Brazilian women with systemic lupus erythematosus. Clin Rheumatol 2018; 37: 1539-1546.

https://doi.org/10.1007/s10067-018-4051-0

17. George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y. Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus 1999; 8(3): 220-226.

https://doi.org/10.1191/096120399678847597

18. Harmouche H, Ammouri W, Maamar M, Adnaoui M, Cacoub P. Atherosclerosis in systemic lupus erythematosus. Presse Medicale 2014; 43(10Pt1): 1034-1047.

https://doi.org/10.1016/j.lpm.2014.01.021